vs

Side-by-side financial comparison of PTC THERAPEUTICS, INC. (PTCT) and WORLD ACCEPTANCE CORP (WRLD). Click either name above to swap in a different company.

PTC THERAPEUTICS, INC. is the larger business by last-quarter revenue ($164.7M vs $141.3M, roughly 1.2× WORLD ACCEPTANCE CORP). WORLD ACCEPTANCE CORP runs the higher net margin — -0.6% vs -82.0%, a 81.3% gap on every dollar of revenue. On growth, WORLD ACCEPTANCE CORP posted the faster year-over-year revenue change (1.9% vs -22.7%). WORLD ACCEPTANCE CORP produced more free cash flow last quarter ($57.2M vs $-36.6M). Over the past eight quarters, WORLD ACCEPTANCE CORP's revenue compounded faster (-5.8% CAGR vs -11.5%).

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.

Credit Acceptance Corporation is an auto finance company providing automobile loans and other related financial products. The company operates its financial program through a national network of dealer-partners, the automobile dealers participating in the programs. The company operates two programs: the "Portfolio Program" and the "Purchase Program". Through these programs, the company can advance money to automobile dealers in exchange for the right to service the underlying consumer loans a...

PTCT vs WRLD — Head-to-Head

Bigger by revenue
PTCT
PTCT
1.2× larger
PTCT
$164.7M
$141.3M
WRLD
Growing faster (revenue YoY)
WRLD
WRLD
+24.6% gap
WRLD
1.9%
-22.7%
PTCT
Higher net margin
WRLD
WRLD
81.3% more per $
WRLD
-0.6%
-82.0%
PTCT
More free cash flow
WRLD
WRLD
$93.8M more FCF
WRLD
$57.2M
$-36.6M
PTCT
Faster 2-yr revenue CAGR
WRLD
WRLD
Annualised
WRLD
-5.8%
-11.5%
PTCT

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
PTCT
PTCT
WRLD
WRLD
Revenue
$164.7M
$141.3M
Net Profit
$-135.0M
$-911.3K
Gross Margin
Operating Margin
-43.3%
-0.7%
Net Margin
-82.0%
-0.6%
Revenue YoY
-22.7%
1.9%
Net Profit YoY
-104.8%
-106.8%
EPS (diluted)
$-1.63
$-0.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PTCT
PTCT
WRLD
WRLD
Q4 25
$164.7M
$141.3M
Q3 25
$211.0M
$134.5M
Q2 25
$178.9M
$132.5M
Q1 25
$1.2B
$165.3M
Q4 24
$213.2M
$138.6M
Q3 24
$196.8M
$131.4M
Q2 24
$186.7M
$129.5M
Q1 24
$210.1M
$159.3M
Net Profit
PTCT
PTCT
WRLD
WRLD
Q4 25
$-135.0M
$-911.3K
Q3 25
$15.9M
$-1.9M
Q2 25
$-64.8M
$1.3M
Q1 25
$866.6M
$44.3M
Q4 24
$-65.9M
$13.4M
Q3 24
$-106.7M
$22.1M
Q2 24
$-99.2M
$9.9M
Q1 24
$-91.6M
$35.1M
Operating Margin
PTCT
PTCT
WRLD
WRLD
Q4 25
-43.3%
-0.7%
Q3 25
1.4%
-1.3%
Q2 25
-19.5%
1.5%
Q1 25
82.5%
33.3%
Q4 24
-76.2%
11.6%
Q3 24
-27.7%
21.3%
Q2 24
-21.5%
10.0%
Q1 24
-21.6%
29.3%
Net Margin
PTCT
PTCT
WRLD
WRLD
Q4 25
-82.0%
-0.6%
Q3 25
7.5%
-1.4%
Q2 25
-36.3%
1.0%
Q1 25
73.7%
26.8%
Q4 24
-30.9%
9.7%
Q3 24
-54.2%
16.8%
Q2 24
-53.1%
7.7%
Q1 24
-43.6%
22.0%
EPS (diluted)
PTCT
PTCT
WRLD
WRLD
Q4 25
$-1.63
$-0.19
Q3 25
$0.20
$-0.38
Q2 25
$-0.83
$0.25
Q1 25
$10.04
$8.07
Q4 24
$-0.85
$2.45
Q3 24
$-1.39
$3.99
Q2 24
$-1.29
$1.79
Q1 24
$-1.20
$6.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PTCT
PTCT
WRLD
WRLD
Cash + ST InvestmentsLiquidity on hand
$1.9B
$10.0M
Total DebtLower is stronger
$677.2M
Stockholders' EquityBook value
$-205.3M
$351.6M
Total Assets
$2.9B
$1.1B
Debt / EquityLower = less leverage
1.93×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PTCT
PTCT
WRLD
WRLD
Q4 25
$1.9B
$10.0M
Q3 25
$1.7B
$14.9M
Q2 25
$2.0B
$8.1M
Q1 25
$2.0B
$4.7M
Q4 24
$1.1B
$10.3M
Q3 24
$1.0B
$9.7M
Q2 24
$1.1B
$11.1M
Q1 24
$884.8M
$5.2M
Total Debt
PTCT
PTCT
WRLD
WRLD
Q4 25
$677.2M
Q3 25
$584.6M
Q2 25
$472.5M
Q1 25
$447.9M
Q4 24
$561.2M
Q3 24
$506.6M
Q2 24
$494.7M
Q1 24
$498.4M
Stockholders' Equity
PTCT
PTCT
WRLD
WRLD
Q4 25
$-205.3M
$351.6M
Q3 25
$-155.8M
$365.6M
Q2 25
$-206.5M
$427.9M
Q1 25
$-185.8M
$439.5M
Q4 24
$-1.1B
$428.2M
Q3 24
$-1.1B
$417.5M
Q2 24
$-980.2M
$422.6M
Q1 24
$-893.9M
$424.4M
Total Assets
PTCT
PTCT
WRLD
WRLD
Q4 25
$2.9B
$1.1B
Q3 25
$2.6B
$1.1B
Q2 25
$2.6B
$1.0B
Q1 25
$2.7B
$1.0B
Q4 24
$1.7B
$1.1B
Q3 24
$1.8B
$1.0B
Q2 24
$1.9B
$1.0B
Q1 24
$1.8B
$1.1B
Debt / Equity
PTCT
PTCT
WRLD
WRLD
Q4 25
1.93×
Q3 25
1.60×
Q2 25
1.10×
Q1 25
1.02×
Q4 24
1.31×
Q3 24
1.21×
Q2 24
1.17×
Q1 24
1.17×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PTCT
PTCT
WRLD
WRLD
Operating Cash FlowLast quarter
$-34.3M
$58.0M
Free Cash FlowOCF − Capex
$-36.6M
$57.2M
FCF MarginFCF / Revenue
-22.3%
40.5%
Capex IntensityCapex / Revenue
1.4%
0.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$702.3M
$412.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PTCT
PTCT
WRLD
WRLD
Q4 25
$-34.3M
$58.0M
Q3 25
$-66.3M
$48.6M
Q2 25
$-58.3M
$58.2M
Q1 25
$870.1M
$254.2M
Q4 24
$-30.0M
$61.1M
Q3 24
$-77.0M
$53.8M
Q2 24
$-71.5M
$48.4M
Q1 24
$70.8M
$265.8M
Free Cash Flow
PTCT
PTCT
WRLD
WRLD
Q4 25
$-36.6M
$57.2M
Q3 25
$-69.7M
$47.7M
Q2 25
$-59.6M
$57.1M
Q1 25
$868.4M
$250.5M
Q4 24
$-33.8M
$60.4M
Q3 24
$-77.5M
$52.7M
Q2 24
$-78.8M
$47.3M
Q1 24
$61.2M
$259.9M
FCF Margin
PTCT
PTCT
WRLD
WRLD
Q4 25
-22.3%
40.5%
Q3 25
-33.1%
35.5%
Q2 25
-33.3%
43.1%
Q1 25
73.8%
151.6%
Q4 24
-15.8%
43.6%
Q3 24
-39.4%
40.1%
Q2 24
-42.2%
36.5%
Q1 24
29.1%
163.2%
Capex Intensity
PTCT
PTCT
WRLD
WRLD
Q4 25
1.4%
0.6%
Q3 25
1.6%
0.7%
Q2 25
0.7%
0.8%
Q1 25
0.1%
2.2%
Q4 24
1.8%
0.5%
Q3 24
0.3%
0.8%
Q2 24
4.0%
0.8%
Q1 24
4.6%
3.7%
Cash Conversion
PTCT
PTCT
WRLD
WRLD
Q4 25
Q3 25
-4.17×
Q2 25
43.27×
Q1 25
1.00×
5.74×
Q4 24
4.56×
Q3 24
2.43×
Q2 24
4.87×
Q1 24
7.58×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons